CoChat
Sign Up
Cited by 26Prostate Cancer Treatment and ResearchChromatin Remodeling and CancerSperm and Testicular Function

CREB5 reprograms FOXA1 nuclear interactions to promote resistance to androgen receptor-targeting therapies

Open access
Hwang, Justin H, Arafeh, Rand, Seo, Ji-Heui, Baca, Sylvan C, Ludwig, Megan, Arnoff, Taylor E, Sawyer, Lydia, Richter, Camden +13 more·2022·eLife
DOI 10.7554/elife.73223PMC PMC9135408

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Metastatic castration-resistant prostate cancers (mCRPCs) are treated with therapies that antagonize the androgen receptor (AR). Nearly all patients develop resistance to AR-targeted therapies (ARTs). Our previous work identified CREB5 as an upregulated target gene in human mCRPC that promoted resistance to all clinically approved ART. The mechanisms by which CREB5 promotes progression of mCRPC or other cancers remains elusive. Integrating ChIP-seq and rapid immunoprecipitation and mass spectroscopy of endogenous proteins, we report that cells overexpressing CREB5 demonstrate extensive reprogramming of nuclear protein–protein interactions in response to the ART agent enzalutamide. Specifically, CREB5 physically interacts with AR, the pioneering actor FOXA1, and other known co-factors of AR and FOXA1 at transcription regulatory elements recently found to be active in mCRPC patients. We identified a subset of CREB5/FOXA1 co-interacting nuclear factors that have critical functions for AR transcription (GRHL2, HOXB13) while others (TBX3, NFIC) regulated cell viability and ART resistance and were amplified or overexpressed in mCRPC. Upon examining the nuclear protein interactions and the impact of CREB5 expression on the mCRPC patient transcriptome, we found that CREB5 was associated with Wnt signaling and epithelial to mesenchymal transitions, implicating these pathways in CREB5/FOXA1-mediated ART resistance. Overall, these observations define the molecular interactions among CREB5, FOXA1, and pathways that promote ART resistance.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7554/elife.73223

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • TBX3 interacts with androgen receptors, playing a key role in the progression and treatment resistance of prostate cancer.

    “TBX3 interacts with androgen receptors, playing a key role in the progression and treatment resistance of prostate cancer 65.”

    From TBX3 shapes an immunosuppressive microenvironment and induces immunotherapy resistance (2025) · cites this paper as [65]

    The Results section ('TBX3 and NFIC are critical for AR-positive prostate cancer cells and ART resistance'; page not provided) links TBX3 to prostate cancer cell viability and resistance to AR-targeted therapy. The Discussion (page not provided) describes TBX3 interacting with CREB5 and FOXA1, not directly with the androgen receptor. The claim’s direct-interaction and prostate-cancer-progression assertions therefore go beyond what these passages establish. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 71 · Cited by 26

Research works printed but not linked: 63

  1. Abida W Cyrta J Heller G Prandi D Armenia J Coleman I Cieslik M Benelli M Robinson D Van Allen EM Sboner A Fedrizzi T Mosquera JM Robinson BD De Sarkar N Kunju LP Tomlins S Wu YM Nava Rodrigues D Loda M Gopalan A Reuter VE Pritchard CC Mateo J Bianchini D Miranda S Carreira S Rescigno P Filipenko J Vinson J Montgomery RB Beltran H Heath EI Scher HI Kantoff PW Taplin ME Schultz N deBono JS Demichelis F Nelson PS Rubin MA Chinnaiyan AM Sawyers CL 2019 Genomic correlates of clinical outcome in advanced prostate cancer PNAS 116 11428 11436 10.1073/pnas.1902651116 31061129 PMC6561293 · DOI · Paper page
  2. Adams EJ Karthaus WR Hoover E Liu D Gruet A Zhang Z Cho H DiLoreto R Chhangawala S Liu Y Watson PA Davicioni E Sboner A Barbieri CE Bose R Leslie CS Sawyers CL 2019 FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes Nature 571 408 412 10.1038/s41586-019-1318-9 31243370 PMC6661172 · DOI
  3. Alumkal JJ Sun D Lu E Beer TM Thomas GV Latour E Aggarwal R Cetnar J Ryan CJ Tabatabaei S Bailey S Turina CB Quigley DA Guan X Foye A Youngren JF Urrutia J Huang J Weinstein AS Friedl V Rettig M Reiter RE Spratt DE Gleave M Evans CP Stuart JM Chen Y Feng FY Small EJ Witte ON Xia Z 2020 Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance PNAS 117 12315 12323 10.1073/pnas.1922207117 32424106 PMC7275746 · DOI
  4. Amir S Simion C Umeh-Garcia M Krig S Moss T Carraway KL Sweeney C 2016 Regulation of the T-box transcription factor Tbx3 by the tumour suppressor microRNA-206 in breast cancer British Journal of Cancer 114 1125 1134 10.1038/bjc.2016.73 27100732 PMC4865973 · DOI · Paper page
  5. Armenia J Wankowicz SAM Liu D Gao J Kundra R Reznik E Chatila WK Chakravarty D Han GC Coleman I Montgomery B Pritchard C Morrissey C Barbieri CE Beltran H Sboner A Zafeiriou Z Miranda S Bielski CM Penson AV Tolonen C Huang FW Robinson D Wu YM Lonigro R Garraway LA Demichelis F Kantoff PW Taplin M-E Abida W Taylor BS Scher HI Nelson PS de Bono JS Rubin MA Sawyers CL Chinnaiyan AM PCF/SU2C International Prostate Cancer Dream Team Schultz N Van Allen EM 2018 The long tail of oncogenic drivers in prostate cancer Nature Genetics 50 645 651 10.1038/s41588-018-0078-z 29610475 PMC6107367 · DOI
  6. Baca SC Takeda DY Seo J-H Hwang J Ku SY Arafeh R Arnoff T Agarwal S Bell C O’Connor E Qiu X Alaiwi SA Corona RI Fonseca MAS Giambartolomei C Cejas P Lim K He M Sheahan A Nassar A Berchuck JE Brown L Nguyen HM Coleman IM Kaipainen A De Sarkar N Nelson PS Morrissey C Korthauer K Pomerantz MM Ellis L Pasaniuc B Lawrenson K Kelly K Zoubeidi A Hahn WC Beltran H Long HW Brown M Corey E Freedman ML 2021 Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer Nature Communications 12 1979 10.1038/s41467-021-22139-7 33785741 PMC8010057 · DOI
  7. Beltran H Prandi D Mosquera JM Benelli M Puca L Cyrta J Marotz C Giannopoulou E Chakravarthi BVSK Varambally S Tomlins SA Nanus DM Tagawa ST Van Allen EM Elemento O Sboner A Garraway LA Rubin MA Demichelis F 2016 Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer Nature Medicine 22 298 305 10.1038/nm.4045 26855148 PMC4777652 · DOI
  8. Bernard D Pourtier-Manzanedo A Gil J Beach DH 2003 Myc confers androgen-independent prostate cancer cell growth The Journal of Clinical Investigation 112 1724 1731 10.1172/JCI19035 14660748 PMC281646 · DOI
  9. Bhardwaj A Singh H Rajapakshe K Tachibana K Ganesan N Pan Y Gunaratne PH Coarfa C Bedrosian I 2017 Regulation of miRNA-29c and its downstream pathways in preneoplastic progression of triple-negative breast cancer Oncotarget 8 19645 19660 10.18632/oncotarget.14902 28160548 PMC5386711 · DOI
  10. Bubley GJ Balk SP 2017 Association Between Androgen Receptor Splice Variants and Prostate Cancer Resistance to Abiraterone and Enzalutamide Journal of Clinical Oncology 35 2103 2105 10.1200/JCO.2017.72.8808 28414609 · DOI
  11. Cerami E Gao J Dogrusoz U Gross BE Sumer SO Aksoy BA Jacobsen A Byrne CJ Heuer ML Larsson E Antipin Y Reva B Goldberg AP Sander C Schultz N 2012 The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data Cancer Discovery 2 401 404 10.1158/2159-8290.CD-12-0095 22588877 PMC3956037 · DOI · Paper page
  12. Chen EY Tan CM Kou Y Duan Q Wang Z Meirelles GV Clark NR Ma’ayan A 2013 Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool BMC Bioinformatics 14 128 10.1186/1471-2105-14-128 23586463 PMC3637064 · DOI · Paper page
  13. Comstock CES Augello MA Goodwin JF de Leeuw R Schiewer MJ Ostrander WF Jr Burkhart RA McClendon AK McCue PA Trabulsi EJ Lallas CD Gomella LG Centenera MM Brody JR Butler LM Tilley WD Knudsen KE 2013 Targeting cell cycle and hormone receptor pathways in cancer Oncogene 32 5481 5491 10.1038/onc.2013.83 23708653 PMC3898261 · DOI
  14. Consortium EP 2012 An integrated encyclopedia of DNA elements in the human genome Nature 489 57 74 10.1038/nature11247 22955616 PMC3439153 · DOI · Paper page
  15. Cowley GS Weir BA Vazquez F Tamayo P Scott JA Rusin S East-Seletsky A Ali LD Gerath WF Pantel SE Lizotte PH Jiang G Hsiao J Tsherniak A Dwinell E Aoyama S Okamoto M Harrington W Gelfand E Green TM Tomko MJ Gopal S Wong TC Wong TC Li H Howell S Stransky N Liefeld T Jang D Bistline J Hill Meyers B Armstrong SA Anderson KC Stegmaier K Reich M Pellman D Boehm JS Mesirov JP Golub TR Root DE Hahn WC 2014 Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies Scientific Data 1 140035 10.1038/sdata.2014.35 25984343 PMC4432652 · DOI
  16. Dwarki VJ Montminy M Verma IM 1990 Both the basic region and the “leucine zipper” domain of the cyclic AMP response element binding (CREB) protein are essential for transcriptional activation The EMBO Journal 9 225 232 10.1002/j.1460-2075.1990.tb08099.x 2136830 PMC551651 · DOI
  17. Eng JK McCormack AL Yates JR 1994 An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database Journal of the American Society for Mass Spectrometry 5 976 989 10.1016/1044-0305(94)80016-2 24226387 · DOI · Paper page
  18. Fuchs SY Ronai Z 1999 Ubiquitination and degradation of ATF2 are dimerization dependent Molecular and Cellular Biology 19 3289 3298 10.1128/MCB.19.5.3289 10207054 PMC84123 · DOI
  19. Gao J Aksoy BA Dogrusoz U Dresdner G Gross B Sumer SO Sun Y Jacobsen A Sinha R Larsson E Cerami E Sander C Schultz N 2013 Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal Science Signaling 6 pl1 10.1126/scisignal.2004088 23550210 PMC4160307 · DOI · Paper page
  20. Gerhardt J Montani M Wild P Beer M Huber F Hermanns T Müntener M Kristiansen G 2012 FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer The American Journal of Pathology 180 848 861 10.1016/j.ajpath.2011.10.021 22138582 · DOI
  21. Glont SE Papachristou EK Sawle A Holmes KA Carroll JS Siersbaek R 2019 Identification of ChIP-seq and RIME grade antibodies for Estrogen Receptor alpha PLOS ONE 14 e0215340 10.1371/journal.pone.0215340 30970003 PMC6457525 · DOI
  22. Grabowska MM Elliott AD DeGraff DJ Anderson PD Anumanthan G Yamashita H Sun Q Friedman DB Hachey DL Yu X Sheehan JH Ahn J-M Raj GV Piston DW Gronostajski RM Matusik RJ 2014 NFI transcription factors interact with FOXA1 to regulate prostate-specific gene expression Molecular Endocrinology (Baltimore, Md.) 28 949 964 10.1210/me.2013-1213 24801505 PMC4042066 · DOI
  23. Grasso CS Wu Y-M Robinson DR Cao X Dhanasekaran SM Khan AP Quist MJ Jing X Lonigro RJ Brenner JC Asangani IA Ateeq B Chun SY Siddiqui J Sam L Anstett M Mehra R Prensner JR Palanisamy N Ryslik GA Vandin F Raphael BJ Kunju LP Rhodes DR Pienta KJ Chinnaiyan AM Tomlins SA 2012 The mutational landscape of lethal castration-resistant prostate cancer Nature 487 239 243 10.1038/nature11125 22722839 PMC3396711 · DOI · Paper page
  24. Han GC Hwang J Wankowicz SAM Zhang Z Liu D Cibulskis C Gaviola GC Ghazikhanian V McKay RR Bubley GJ Carter SL Balk SP Hahn WC Taplin M-E Van Allen EM 2017 Genomic Resistance Patterns to Second-Generation Androgen Blockade in Paired Tumor Biopsies of Metastatic Castration-Resistant Prostate Cancer JCO Precision Oncology 1 1 11 10.1200/PO.17.00140 32913968 PMC7446377 · DOI
  25. He S Deng Y Liao Y Li X Liu J Yao S 2017 CREB5 promotes tumor cell invasion and correlates with poor prognosis in epithelial ovarian cancer Oncology Letters 14 8156 8161 10.3892/ol.2017.7234 29250192 PMC5727587 · DOI
  26. He MX Cuoco MS Crowdis J Bosma-Moody A Zhang Z Bi K Kanodia A Su M-J Ku S-Y Garcia MM Sweet AR Rodman C DelloStritto L Silver R Steinharter J Shah P Izar B Walk NC Burke KP Bakouny Z Tewari AK Liu D Camp SY Vokes NI Salari K Park J Vigneau S Fong L Russo JW Yuan X Balk SP Beltran H Rozenblatt-Rosen O Regev A Rotem A Taplin M-E Van Allen EM 2021 Transcriptional mediators of treatment resistance in lethal prostate cancer Nature Medicine 27 426 433 10.1038/s41591-021-01244-6 33664492 PMC7960507 · DOI
  27. Heinz S Benner C Spann N Bertolino E Lin YC Laslo P Cheng JX Murre C Singh H Glass CK 2010 Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities Molecular Cell 38 576 589 10.1016/j.molcel.2010.05.004 20513432 PMC2898526 · DOI · Paper page
  28. Hong AL Tseng Y-Y Wala JA Kim W-J Kynnap BD Doshi MB Kugener G Sandoval GJ Howard TP Li J Yang X Tillgren M Ghandi M Sayeed A Deasy R Ward A McSteen B Labella KM Keskula P Tracy A Connor C Clinton CM Church AJ Crompton BD Janeway KA Van Hare B Sandak D Gjoerup O Bandopadhayay P Clemons PA Schreiber SL Root DE Gokhale PC Chi SN Mullen EA Roberts CW Kadoch C Beroukhim R Ligon KL Boehm JS Hahn WC 2019 Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition eLife 8 e44161 10.7554/eLife.44161 30860482 PMC6436895 · DOI
  29. Howard TP Arnoff TE Song MR Giacomelli AO Wang X Hong AL Dharia NV Wang S Vazquez F Pham MT Morgan AM Wachter F Bird GH Kugener G Oberlick EM Rees MG Tiv HL Hwang JH Walsh KH Cook A Krill-Burger JM Tsherniak A Gokhale PC Park PJ Stegmaier K Walensky LD Hahn WC Roberts CWM 2019 MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors Cancer Research 79 2404 2414 10.1158/0008-5472.CAN-18-3066 30755442 PMC6497578 · DOI
  30. Hwang JH Seo J-H Beshiri ML Wankowicz S Liu D Cheung A Li J Qiu X Hong AL Botta G Golumb L Richter C So J Sandoval GJ Giacomelli AO Ly SH Han C Dai C Pakula H Sheahan A Piccioni F Gjoerup O Loda M Sowalsky AG Ellis L Long H Root DE Kelly K Van Allen EM Freedman ML Choudhury AD Hahn WC 2019 CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer Cell Reports 29 2355 2370 10.1016/j.celrep.2019.10.068 31747605 PMC6886683 · DOI
  31. Isaacsson Velho P Fu W Wang H Mirkheshti N Qazi F Lima FAS Shaukat F Carducci MA Denmeade SR Paller CJ Markowski MC Marshall CH Eisenberger MA Antonarakis ES 2020 Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer European Urology 77 14 21 10.1016/j.eururo.2019.05.032 31176623 PMC6893106 · DOI
  32. Jin L Garcia J Chan E de la Cruz C Segal E Merchant M Kharbanda S Raisner R Haverty PM Modrusan Z Ly J Choo E Kaufman S Beresini MH Romero FA Magnuson S Gascoigne KE 2017 Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer Cancer Research 77 5564 5575 10.1158/0008-5472.CAN-17-0314 28819026 · DOI · Paper page
  33. Johnson WE Li C Rabinovic A 2007 Adjusting batch effects in microarray expression data using empirical Bayes methods Biostatistics (Oxford, England) 8 118 127 10.1093/biostatistics/kxj037 16632515 · DOI · Paper page
  34. Kregel S Chen JL Tom W Krishnan V Kach J Brechka H Fessenden TB Isikbay M Paner GP Szmulewitz RZ Vander Griend DJ 2016 Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer Oncotarget 7 26259 26274 10.18632/oncotarget.8456 27036029 PMC5041979 · DOI
  35. Krstic M Macmillan CD Leong HS Clifford AG Souter LH Dales DW Postenka CO Chambers AF Tuck AB 2016 The transcriptional regulator TBX3 promotes progression from non-invasive to invasive breast cancer BMC Cancer 16 671 10.1186/s12885-016-2697-z 27553211 PMC4994202 · DOI · Paper page
  36. Kuleshov MV Jones MR Rouillard AD Fernandez NF Duan Q Wang Z Koplev S Jenkins SL Jagodnik KM Lachmann A McDermott MG Monteiro CD Gundersen GW Ma’ayan A 2016 Enrichr: a comprehensive gene set enrichment analysis web server 2016 update Nucleic Acids Research 44 W90 W97 10.1093/nar/gkw377 27141961 PMC4987924 · DOI · Paper page
  37. Lasko LM Jakob CG Edalji RP Qiu W Montgomery D Digiammarino EL Hansen TM Risi RM Frey R Manaves V Shaw B Algire M Hessler P Lam LT Uziel T Faivre E Ferguson D Buchanan FG Martin RL Torrent M Chiang GG Karukurichi K Langston JW Weinert BT Choudhary C de Vries P Van Drie JH McElligott D Kesicki E Marmorstein R Sun C Cole PA Rosenberg SH Michaelides MR Lai A Bromberg KD 2017 Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours Nature 550 128 132 10.1038/nature24028 28953875 PMC6050590 · DOI · Paper page
  38. Launonen K-M Paakinaho V Sigismondo G Malinen M Sironen R Hartikainen JM Laakso H Visakorpi T Krijgsveld J Niskanen EA Palvimo JJ 2021 Chromatin-directed proteomics-identified network of endogenous androgen receptor in prostate cancer cells Oncogene 40 4567 4579 10.1038/s41388-021-01887-2 34127815 PMC8266679 · DOI
  39. Layer RM Pedersen BS DiSera T Marth GT Gertz J Quinlan AR 2018 GIGGLE: a search engine for large-scale integrated genome analysis Nature Methods 15 123 126 10.1038/nmeth.4556 29309061 PMC5872823 · DOI
  40. Lee E Ha S Logan SK 2015 Divergent Androgen Receptor and Beta-Catenin Signaling in Prostate Cancer Cells PLOS ONE 10 e0141589 10.1371/journal.pone.0141589 26509262 PMC4624871 · DOI
  41. Leek JT Johnson WE Parker HS Jaffe AE Storey JD 2012 The sva package for removing batch effects and other unwanted variation in high-throughput experiments Bioinformatics (Oxford, England) 28 882 883 10.1093/bioinformatics/bts034 22257669 PMC3307112 · DOI · Paper page
  42. Luo Q Viste K Urday-Zaa JC Senthil Kumar G Tsai WW Talai A Mayo KE Montminy M Radhakrishnan I 2012 Mechanism of CREB recognition and coactivation by the CREB-regulated transcriptional coactivator CRTC2 PNAS 109 20865 20870 10.1073/pnas.1219028109 23213254 PMC3529076 · DOI
  43. Marshall TW Link KA Petre-Draviam CE Knudsen KE 2003 Differential requirement of SWI/SNF for androgen receptor activity The Journal of Biological Chemistry 278 30605 30613 10.1074/jbc.M304582200 12775722 · DOI
  44. Mohammed H Taylor C Brown GD Papachristou EK Carroll JS D’Santos CS 2016 Rapid immunoprecipitation mass spectrometry of endogenous proteins (RIME) for analysis of chromatin complexes Nature Protocols 11 316 326 10.1038/nprot.2016.020 26797456 · DOI
  45. Molnár B Galamb O Péterfia B Wichmann B Csabai I Bodor A Kalmár A Szigeti KA Barták BK Nagy ZB Valcz G Patai ÁV Igaz P Tulassay Z 2018 Gene promoter and exon DNA methylation changes in colon cancer development - mRNA expression and tumor mutation alterations BMC Cancer 18 695 10.1186/s12885-018-4609-x 29945573 PMC6020382 · DOI
  46. Murillo-Garzón V Kypta R 2017 WNT signalling in prostate cancer Nature Reviews. Urology 14 683 696 10.1038/nrurol.2017.144 28895566 · DOI
  47. Nakshatri H Badve S 2009 FOXA1 in breast cancer Expert Reviews in Molecular Medicine 11 e8 10.1017/S1462399409001008 19261198 · DOI
  48. Nguyen HM Vessella RL Morrissey C Brown LG Coleman IM Higano CS Mostaghel EA Zhang X True LD Lam H-M Roudier M Lange PH Nelson PS Corey E 2017 LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics The Prostate 77 654 671 10.1002/pros.23313 28156002 PMC5354949 · DOI
  49. Nomura N Zu YL Maekawa T Tabata S Akiyama T Ishii S 1993 Isolation and characterization of a novel member of the gene family encoding the cAMP response element-binding protein CRE-BP1 The Journal of Biological Chemistry 268 4259 4266 8440710
  50. Paltoglou S Das R Townley SL Hickey TE Tarulli GA Coutinho I Fernandes R Hanson AR Denis I Carroll JS Dehm SM Raj GV Plymate SR Tilley WD Selth LA 2017 Novel Androgen Receptor Coregulator GRHL2 Exerts Both Oncogenic and Antimetastatic Functions in Prostate Cancer Cancer Research 77 3417 3430 10.1158/0008-5472.CAN-16-1616 28473532 PMC5497757 · DOI
  51. Peng J Gygi SP 2001 Proteomics: the move to mixtures Journal of Mass Spectrometry 36 1083 1091 10.1002/jms.229 11747101 · DOI
  52. Pomerantz MM Li F Takeda DY Lenci R Chonkar A Chabot M Cejas P Vazquez F Cook J Shivdasani RA Bowden M Lis R Hahn WC Kantoff PW Brown M Loda M Long HW Freedman ML 2015 The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis Nature Genetics 47 1346 1351 10.1038/ng.3419 26457646 PMC4707683 · DOI · Paper page
  53. Pomerantz MM Qiu X Zhu Y Takeda DY Pan W Baca SC Gusev A Korthauer KD Severson TM Ha G Viswanathan SR Seo J-H Nguyen HM Zhang B Pasaniuc B Giambartolomei C Alaiwi SA Bell CA O’Connor EP Chabot MS Stillman DR Lis R Font-Tello A Li L Cejas P Bergman AM Sanders J van der Poel HG Gayther SA Lawrenson K Fonseca MAS Reddy J Corona RI Martovetsky G Egan B Choueiri T Ellis L Garraway IP Lee G-SM Corey E Long HW Zwart W Freedman ML 2020 Prostate cancer reactivates developmental epigenomic programs during metastatic progression Nature Genetics 52 790 799 10.1038/s41588-020-0664-8 32690948 PMC10007911 · DOI
  54. Qi L Ding Y 2014 Involvement of the CREB5 regulatory network in colorectal cancer metastasis Yi Chuan = Hereditas 36 679 684 10.3724/SP.J.1005.2014.0679 25076032 · DOI
  55. Quinlan AR Hall IM 2010 BEDTools: a flexible suite of utilities for comparing genomic features Bioinformatics (Oxford, England) 26 841 842 10.1093/bioinformatics/btq033 20110278 PMC2832824 · DOI · Paper page
  56. Robinson D Van Allen EM Wu Y-M Schultz N Lonigro RJ Mosquera J-M Montgomery B Taplin M-E Pritchard CC Attard G Beltran H Abida W Bradley RK Vinson J Cao X Vats P Kunju LP Hussain M Feng FY Tomlins SA Cooney KA Smith DC Brennan C Siddiqui J Mehra R Chen Y Rathkopf DE Morris MJ Solomon SB Durack JC Reuter VE Gopalan A Gao J Loda M Lis RT Bowden M Balk SP Gaviola G Sougnez C Gupta M Yu EY Mostaghel EA Cheng HH Mulcahy H True LD Plymate SR Dvinge H Ferraldeschi R Flohr P Miranda S Zafeiriou Z Tunariu N Mateo J Perez-Lopez R Demichelis F Robinson BD Sboner A Schiffman M Nanus DM Tagawa ST Sigaras A Eng KW Elemento O Sboner A Heath EI Scher HI Pienta KJ Kantoff P de Bono JS Rubin MA Nelson PS Garraway LA Sawyers CL Chinnaiyan AM 2015 Integrative Clinical Genomics of Advanced Prostate Cancer Cell 162 454 10.1016/j.cell.2015.06.053 28843286 · DOI
  57. Shah N Brown M 2019 The Sly Oncogene: FOXA1 Mutations in Prostate Cancer Cancer Cell 36 119 121 10.1016/j.ccell.2019.07.005 31408618 · DOI
  58. Shalem O Sanjana NE Hartenian E Shi X Scott DA Mikkelson T Heckl D Ebert BL Root DE Doench JG Zhang F 2014 Genome-scale CRISPR-Cas9 knockout screening in human cells Science (New York, N.Y.) 343 84 87 10.1126/science.1247005 24336571 PMC4089965 · DOI · Paper page
  59. Sharma NL Massie CE Ramos-Montoya A Zecchini V Scott HE Lamb AD MacArthur S Stark R Warren AY Mills IG Neal DE 2013 The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man Cancer Cell 23 35 47 10.1016/j.ccr.2012.11.010 23260764 · DOI
  60. Shevchenko A Wilm M Vorm O Mann M 1996 Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels Analytical Chemistry 68 850 858 10.1021/ac950914h 8779443 · DOI
  61. Sinha A Huang V Livingstone J Wang J Fox NS Kurganovs N Ignatchenko V Fritsch K Donmez N Heisler LE Shiah Y-J Yao CQ Alfaro JA Volik S Lapuk A Fraser M Kron K Murison A Lupien M Sahinalp C Collins CC Tetu B Masoomian M Berman DM van der Kwast T Bristow RG Kislinger T Boutros PC 2019 The Proteogenomic Landscape of Curable Prostate Cancer Cancer Cell 35 414 427 10.1016/j.ccell.2019.02.005 30889379 PMC6511374 · DOI
  62. Tsherniak A Vazquez F Montgomery PG Weir BA Kryukov G Cowley GS Gill S Harrington WF Pantel S Krill-Burger JM Meyers RM Ali L Goodale A Lee Y Jiang G Hsiao J Gerath WFJ Howell S Merkel E Ghandi M Garraway LA Root DE Golub TR Boehm JS Hahn WC 2017 Defining a Cancer Dependency Map Cell 170 564 576 10.1016/j.cell.2017.06.010 28753430 PMC5667678 · DOI · Paper page
  63. Welti J Sharp A Brooks N Yuan W McNair C Chand SN Pal A Figueiredo I Riisnaes R Gurel B Rekowski J Bogdan D West W Young B Raja M Prosser A Lane J Thomson S Worthington J Onions S Shannon J Paoletta S Brown R Smyth D Harbottle GW Gil VS Miranda S Crespo M Ferreira A Pereira R Tunariu N Carreira S Neeb AJ Ning J Swain A Taddei D SU2C/PCF International Prostate Cancer Dream Team Schiewer MJ Knudsen KE Pegg N de Bono JS 2021 Targeting the p300/CBP Axis in Lethal Prostate Cancer Cancer Discovery 11 1118 1137 10.1158/2159-8290.CD-20-0751 33431496 PMC8102310 · DOI

Authors
Hwang, J. H., Arafeh, R., Seo, J.-H., Baca, S. C., Ludwig, M., Arnoff, T. E., Sawyer, L., Richter, C., Tape, S., Bergom, H. E., McSweeney, S., Rennhack, J. P., Klingenberg, S. A., Cheung, A. T., Kwon, J., So, J., Kregel, S., Van Allen, E. M., Drake, J. M., Freedman, M. L., & Hahn, W. C.
Affiliations
  • University of Minnesota (US)
  • Broad Institute (US)
  • Brown University (US)
  • Dana-Farber Cancer Institute (US)
  • Loyola University Chicago (US)
  • Department of Medical Oncology, Dana-Farber Cancer Institute
Corresponding author
  • Hwang, Justin H
  • Hahn, William C
ORCID
Venue
eLife
Publisher
eLife Sciences Publications, Ltd
Published
2022-05-12
Volume
11
ISSN
2050-084X (ISSN-L)
DOI
10.7554/elife.73223
PMC
PMC9135408
OpenAlex
W4280575152
Cited by
26
References
71
Citations by year
2026: 2 · 2025: 9 · 2024: 6 · 2023: 8 · 2022: 1
FWCI
3.87
Type
journal article
Language
en
Open access
Licence
Locations
  • eLife (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • University of Minnesota (Start up funds)
  • National Cancer Institute (U01 CA176058, U01 CA233100)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Treatment and Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
  • Health Sciences › Medicine › Reproductive Medicine › Sperm and Testicular Function
Keywords
CREB5, FOXA1, androgen receptor, castration-resistant prostate cancer, enzalutamide, transcriptional cofactors, GRHL2, HOXB13, TBX3, NFIC, Wnt signaling, epithelial-mesenchymal transition, transcriptional reprogramming
MeSH terms
Cell Nucleus, Humans, Male, Receptors, Androgen, Cell Line, Tumor, Hepatocyte Nuclear Factor 3-alpha, Cyclic AMP Response Element-Binding Protein A, Prostatic Neoplasms, Castration-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review